modelD02BA02
Extends from Pharmacokinetic.Models.PK_1C.
Information
| name: | Octinoxate | |
| ATC code: | D02BA02 | route: | topical |
| compartments: | 1 | |
| dosage: | 10 | mg |
| volume of distribution: | 3 | L |
| clearance: | 0.2 | L/h/kg |
| other parameters in model implementation | ||
Octinoxate (octyl methoxycinnamate or ethylhexyl methoxycinnamate) is an organic compound used primarily as a UV-B filter in sunscreens, cosmetics, and skin care products for the prevention of sunburn and photodamage. It is used topically and is approved in many countries for over-the-counter use for skin protection against the harmful effects of solar ultraviolet radiation.
Pharmacokinetics
Estimated pharmacokinetic parameters for healthy adults; specific human PK data are lacking in primary literature.
References
Hayden, CG, et al., & Roberts, MS (2005). Sunscreen penetration of human skin and related keratinocyte toxicity after topical application. Skin pharmacology and physiology 18(4) 170–174. DOI:10.1159/000085861 PUBMED:https://pubmed.ncbi.nlm.nih.gov/15908756
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)